Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

被引：34
|
作者：
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 08期
关键词：
SARCOMATOID CARCINOMA; AMPLIFICATION; CRIZOTINIB; GEFITINIB; PATIENT; CBL; UBIQUITINATION; RESPONSIVENESS; CHEMOTHERAPY; SENSITIVITY;
D O I：
10.1200/JCO.2015.64.2777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：879 / +
页数：5
相关论文
共 50 条
  • [41] The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
    Zhu, Y.
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 5 - 5
  • [42] Retrospective Analysis to Optimize the Detection of MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer
    Lu, Jang-Jih
    Tsai, Shu-Hui
    Lin, Lee-Chung
    Chiueh, Tzong-Shi
    DIAGNOSTICS, 2024, 14 (11)
  • [43] Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer
    Kim, Eun Kyung
    Kim, Kyung A.
    Lee, Chang Young
    Kim, Sangwoo
    Chang, Sunhee
    Cho, Byoung Chul
    Shim, Hyo Sup
    CLINICAL LUNG CANCER, 2019, 20 (01) : E123 - E132
  • [44] HGF/c-Met Overexpressions, but not Met Mutation, Correlates with Progression of Non-small Cell Lung Cancer
    Gumustekin, Mukaddes
    Kargi, Aydanur
    Bulut, Gulay
    Gozukizil, Aysim
    Ulukus, Cagnur
    Oztop, Ilhan
    Atabey, Nese
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (02) : 209 - 218
  • [45] Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
    Awad, Mark M.
    Leonardi, Giulia C.
    Kravets, Sasha
    Dahlberg, Suzanne E.
    Drilon, Alexander
    Noonan, Sinead A.
    Camidge, D. Ross
    Ou, Sai-Hong, I
    Costa, Daniel B.
    Gadgeel, Shirish M.
    Steuer, Conor E.
    Forde, Patrick M.
    Zhu, Viola W.
    Fukuda, Yoko
    Clark, Jeffrey W.
    Janne, Pasi A.
    Mok, Tony
    Sholl, Lynette M.
    Heist, Rebecca S.
    LUNG CANCER, 2019, 133 : 96 - 102
  • [46] Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1046 - S1046
  • [47] MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
    Ramesh, Shrey
    Cifci, Ahmet
    Javeri, Saahil
    Minne, Rachel L.
    Longhurst, Colin A.
    Nickel, Kwangok P.
    Kimple, Randall J.
    Baschnagel, Andrew M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1379 - 1390
  • [48] MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis
    Lambros, Laetitia
    Uguen, Arnaud
    CLINICAL LUNG CANCER, 2019, 20 (03) : E418 - E420
  • [49] Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.
    Palk, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Scheele, Jurgen
    Bruns, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Non-small-Cell Lung Cancer
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Rossi, Antonio
    Rossi, Emanuela
    Napolitano, Alba
    Palazzolo, Giovanni
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Ciardiello, Fortunato
    Gridelli, Cesare
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (37) : 6155 - 6168
12345